Assembly Biosciences Total Current Assets 2010-2024 | ASMB

Assembly Biosciences total current assets from 2010 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Assembly Biosciences Annual Total Current Assets
(Millions of US $)
2023 $134
2022 $97
2021 $154
2020 $224
2019 $283
2018 $223
2017 $123
2016 $54
2015 $68
2014 $29
2013 $27
2012 $21
2011 $37
2010 $15
2009 $0
Assembly Biosciences Quarterly Total Current Assets
(Millions of US $)
2024-09-30 $98
2024-06-30 $113
2024-03-31 $117
2023-12-31 $134
2023-09-30 $50
2023-06-30 $64
2023-03-31 $80
2022-12-31 $97
2022-09-30 $115
2022-06-30 $124
2022-03-31 $131
2021-12-31 $154
2021-09-30 $188
2021-06-30 $206
2021-03-31 $222
2020-12-31 $224
2020-09-30 $246
2020-06-30 $235
2020-03-31 $257
2019-12-31 $283
2019-09-30 $165
2019-06-30 $183
2019-03-31 $201
2018-12-31 $223
2018-09-30 $240
2018-06-30 $98
2018-03-31 $113
2017-12-31 $123
2017-09-30 $69
2017-06-30 $78
2017-03-31 $92
2016-12-31 $54
2016-09-30 $59
2016-06-30 $64
2016-03-31 $59
2015-12-31 $68
2015-09-30 $67
2015-06-30 $71
2015-03-31 $96
2014-12-31 $29
2014-09-30 $18
2014-06-30 $22
2014-03-31 $24
2013-12-31 $27
2013-09-30 $32
2013-06-30 $34
2013-03-31 $37
2012-12-31 $21
2012-09-30 $24
2012-06-30 $29
2012-03-31 $31
2011-12-31 $37
2011-09-30 $53
2011-06-30 $11
2011-03-31 $14
2010-12-31 $15
2010-09-30
2010-06-30
2010-03-31
2009-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.094B $0.007B
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
Dr Reddy's Laboratories (RDY) India $11.677B 22.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Personalis (PSNL) United States $0.239B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00